Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Fraser

Showing results (551-560 of 598) with videos related to

Pageof 60
Sort By:
Breast Cancer Research and Treatment|December 3, 2024
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancerHope S Rugo, Mike Campbell, Christina Yau, et al.
Biorxiv : the Preprint Server for Biology|December 9, 2024
An annotated biobank of triple negative breast cancer patient-derived xenografts featuring treatment-naïve and longitudinal samples throughout neoadjuvant chemotherapyAmanda L Rinkenbaugh, Yuan Qi, Shirong Cai, et al.
Energy & Environmental Science|October 14, 2024
Distinguishing bulk redox from near-surface degradation in lithium nickel oxide cathodesLijin An, Jack E N Swallow, Peixi Cong, et al.
JAMA|October 9, 2013
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trialJudy C Boughey, Vera J Suman, Elizabeth A Mittendorf, et al.
Cancer Research|August 13, 2025
An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples During Neoadjuvant ChemotherapyAmanda L Rinkenbaugh, Yuan Qi, Shirong Cai, et al.
Breast Cancer Research and Treatment|April 15, 2023
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancerClinton Yam, Elizabeth A Mittendorf, Haven R Garber, et al.
Journal of the National Cancer Institute|June 25, 2014
Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancerEnrique Fuentes-Mattei, Guermarie Velazquez-Torres, Liem Phan, et al.
JACC. Cardiovascular Interventions|March 15, 2023
Clinical Impact of Standardized TAVR Technique and Care Pathway: Insights From the Optimize PRO StudyKendra J Grubb, Hemal Gada, Suneet Mittal, et al.
JAMA|May 12, 2011
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancerChristos Hatzis, Lajos Pusztai, Vicente Valero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2026
Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trialMiguel Martín, Alvaro Rodriguez-Lescure, Cristina Reboredo, et al.
Pageof 60

Showing results (551-560 of 598) with videos related to

Sort By:
Pageof 60
Breast Cancer Research and Treatment|December 3, 2024
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancerHope S Rugo, Mike Campbell, Christina Yau, et al.
Biorxiv : the Preprint Server for Biology|December 9, 2024
An annotated biobank of triple negative breast cancer patient-derived xenografts featuring treatment-naïve and longitudinal samples throughout neoadjuvant chemotherapyAmanda L Rinkenbaugh, Yuan Qi, Shirong Cai, et al.
Energy & Environmental Science|October 14, 2024
Distinguishing bulk redox from near-surface degradation in lithium nickel oxide cathodesLijin An, Jack E N Swallow, Peixi Cong, et al.
JAMA|October 9, 2013
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trialJudy C Boughey, Vera J Suman, Elizabeth A Mittendorf, et al.
Cancer Research|August 13, 2025
An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples During Neoadjuvant ChemotherapyAmanda L Rinkenbaugh, Yuan Qi, Shirong Cai, et al.
Breast Cancer Research and Treatment|April 15, 2023
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancerClinton Yam, Elizabeth A Mittendorf, Haven R Garber, et al.
Journal of the National Cancer Institute|June 25, 2014
Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancerEnrique Fuentes-Mattei, Guermarie Velazquez-Torres, Liem Phan, et al.
JACC. Cardiovascular Interventions|March 15, 2023
Clinical Impact of Standardized TAVR Technique and Care Pathway: Insights From the Optimize PRO StudyKendra J Grubb, Hemal Gada, Suneet Mittal, et al.
JAMA|May 12, 2011
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancerChristos Hatzis, Lajos Pusztai, Vicente Valero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2026
Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trialMiguel Martín, Alvaro Rodriguez-Lescure, Cristina Reboredo, et al.
Pageof 60